Sign In
Buy ZNTL
$4.74
-0.180 (-3.66%)
At Close: Jul 31, 2026
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
10:00am, Wednesday, 31'st Jul 2024
NEW YORK, NY / ACCESSWIRE / July 31, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. ("Zentalis" or the "Company") (NASDAQ:ZNTL). Such investors a
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
10:43am, Friday, 26'th Jul 2024
NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. (“Zentalis” or the “Company”) (NASDAQ: ZNTL). Such
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
08:00pm, Wednesday, 24'th Jul 2024
NEW YORK , July 24, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. ("Zentalis" or the "Company") (NASDAQ: ZNTL). Such investors
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
04:30pm, Tuesday, 23'rd Jul 2024
NEW YORK, NY / ACCESSWIRE / July 23, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. ("Zentalis" or the "Company") (NASDAQ:ZNTL). Such investors a
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
12:00pm, Sunday, 14'th Jul 2024
NEW YORK, NY / ACCESSWIRE / July 14, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. ("Zentalis" or the "Company") (NASDAQ:ZNTL). Such investors a
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
10:08am, Friday, 12'th Jul 2024
NEW YORK, July 12, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. (“Zentalis” or the “Company”) (NASDAQ: ZNTL). Such
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
06:12pm, Wednesday, 10'th Jul 2024
NEW YORK , July 10, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. ("Zentalis" or the "Company") (NASDAQ: ZNTL). Such investors a
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
01:02pm, Sunday, 07'th Jul 2024
NEW YORK, July 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. (“Zentalis” or the “Company”) (NASDAQ: ZNTL). Such
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
12:00pm, Friday, 05'th Jul 2024
NEW YORK, NY / ACCESSWIRE / July 5, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. ("Zentalis" or the "Company") (NASDAQ:ZNTL). Such investors ar
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
08:30am, Tuesday, 02'nd Jul 2024
NEW YORK , July 2, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. ("Zentalis" or the "Company") (NASDAQ: ZNTL). Such investors a
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06:00pm, Monday, 01'st Jul 2024
SAN DIEGO, July 01, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small mole
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
03:33pm, Sunday, 30'th Jun 2024
NEW YORK, June 30, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. (“Zentalis” or the “Company”) (NASDAQ: ZNTL). Such
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
02:30pm, Wednesday, 26'th Jun 2024
NEW YORK, NY / ACCESSWIRE / June 26, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. ("Zentalis" or the "Company") (NASDAQ:ZNTL). Such investors a
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
03:56pm, Monday, 24'th Jun 2024
NEW YORK , June 24, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. ("Zentalis" or the "Company") (NASDAQ: ZNTL). Such investors are
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
05:15pm, Friday, 21'st Jun 2024
NEW YORK, NY / ACCESSWIRE / June 21, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. ("Zentalis" or the "Company") (NASDAQ:ZNTL). Such investors a
